1. Randhawa HK, Sibbald C, Garcia Romero MT, Pope E. Oral nadolol for the treatment of infantile hemangiomas:

a single-institution retrospective cohort study. Pediatr Dermatol. 2015;32(5): 690–695

2. Droitcourt C, Kerbrat S, Rault C, et al. Safety of oral propranolol for infantile hemangioma. Pediatrics. 2018;141(6): e20173783

3. Pope E, Chakkittakandiyil A, Lara- Corrales I, Maki E, Weinstein M. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013; 168(1):222–224

4. Bernabeu-Wittel J, Narváez-Moreno B, de la Torre-García JM, et al. Oral nadolol for children with infantile hemangiomas and sleep disturbances with oral propranolol. Pediatr Dermatol. 2015;32(6):853–857

5. AA Pharma Inc. Product monograph: nadolol. 2016. Available at: https:// www.aapharma.ca/downloads/en/PIL/ 2016/Nadolol\_pm.pdf. Accessed Aug. 10, 2018

6. Dreyfuss J, Brannick LJ, Vukovich RA, Shaw JM, Willard DA. Metabolic studies in patients with nadolol: oral and intravenous administration. J Clin Pharmacol. 1977;17(5–6):300–307

7. Dreyfuss J, Griffith DL, Singhvi SM, et al. Pharmacokinetics of nadolol, a beta- receptor antagonist: administration

of therapeutic single- and multiple- dosage regimens to hypertensive patients. J Clin Pharmacol. 1979; 19(11–12):712–720

8. du Souich P, Caillé G, Larochelle P. Enhancement of nadolol elimination by activated charcoal and antibiotics. Clin Pharmacol Ther. 1983;33(5): 585–590

9. Mehta AV, Chidambaram B, Rice PJ. Pharmacokinetics of nadolol in children with supraventricular tachycardia. J Clin Pharmacol. 1992;32(11):1023–1027

10. FDA. Product monograph: propranolol. 2010. Available at: https://www.acce ssdata.fda.gov/drugsatfda\_docs/label/ 2011/016418s080,016762s017,017683s008lbl. pdf. Accessed Aug. 14, 2019

11. Poterucha JT, Bos JM, Cannon BC, Ackerman MJ. Frequency and severity of hypoglycemia in children with beta-blocker-treated long QT syndrome. Heart Rhythm. 2015;12(8): 1815–1819

12. von Alvensleben JC, LaPage MJ, Caruthers R, Bradley DJ. Nadolol for treatment of supraventricular tachycardia in infants and young children. Pediatr Cardiol. 2017;38(3): 525–530

13. Devlin RG, Duchin KL, Fleiss PM. Nadolol in human serum and breast milk. Br J Clin Pharmacol. 1981;12(3): 393–396

14. McKinney P, Lawrence L. Nadolol toxicity treated with hemodialysis. J Toxicol Clin Toxicol. 1995;33:517

15. Ehgartner GR, Zelinka MA. Hemodynamic instability following intentional nadolol overdose. Arch Intern Med. 1988;148(4):801–802